Overview
Calla Lily Clinical Care develops Callavid®, a patented, leak-free, tampon-shaped intravaginal drug delivery device for consistent administration of therapeutics. Initial focus is on progesterone for miscarriage prevention and IVF support, with potential for oncology, menopause, bacterial vaginosis, and microbiome therapies. The FDA-cleared platform has secured NIHR funding, Innovate UK grants, and a 2026 strategic collaboration with Merck.
Frequently asked questions
- What is Callavid and its key capabilities?
- Callavid is a patented, tampon-shaped device providing leak-free, dosage-confident intravaginal drug delivery. It supports hygienic insertion, in-place absorption, and clean removal for therapeutics in fertility, pregnancy, oncology, menopause, and infections.
- What regulatory approvals and funding has the company received?
- Callavid's underlying technology has FDA clearance. The company has raised £2.3 million in funding, over £2 million in Innovate UK and NIHR grants, and announced a Merck collaboration in 2026.
- What geographies does Calla Lily Clinical Care serve?
- London-based, operating primarily in the United Kingdom with FDA clearance indicating US market potential. Clinical trials are progressing in the UK, targeting global women's health applications.